One of the hallmarks of CML, is the increase in cell proliferation.36 TKIs, which directly target the activation of Bcr‐Abl, inhibit proliferation of bulk CML cells; however, a fraction of LSC has been shown to enter quiescence and avoid apoptosis.15 Here, we found that a fraction of CML cells is able to survive PTL and DMAPT treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.